Abstract Diagnosis and management of coronary artery disease represent a major challenge to our health care systems affecting millions of patients each year. Until recently, the diagnosis of coronary artery disease could be conclusively determined only by invasive coronary angiography. To avoid risks from cardiac catheterization, many health care systems rely on stress testing as gatekeeper for coronary angiography. Advancements in cardiac computed tomography angiography technology now allows for the accurate noninvasive visualization of coronary artery disease, challenging the role of stress testing as the default noninvasive imaging tool for evaluating patients with chest pain. In this review, we summarize current data on the clinical utility of cardiac computed tomography and stress testing in stable patients with suspected coronary artery disease.
Introduction
Cardiovascular diseases, and particular, coronary artery disease (CAD), remain the leading cause of death worldwide with an enormous burden on health care systems [1] . More than 10 million stress tests and approximately one million diagnostic cardiac catheterizations are performed annually in the USA alone [1] . Total costs of cardiovascular disease and stroke in the USA for 2015 are estimated to exceed 320 billion dollars [1] . Management of CAD requires an accurate diagnosis. For many decades, invasive coronary angiography (ICA) has served as gold standard for the diagnosis of CAD despite many well-recognized limitations of this seasoned technology [2, 3] . To avoid risks from cardiac catheterization in lowintermediate-risk patients, myocardial stress testing has been widely utilized as gatekeeper for invasive angiography. The emergence of multidetector computed tomography technology has allowed to noninvasively assess the presence, location, severity, and characteristics of coronary atherosclerotic disease in patients. In recent years, an abundance of clinical studies revealed data on the diagnostic and prognostic performance of cardiac computed tomography angiography (CCTA), challenging the role of stress testing as the default noninvasive test for patients presenting with nonacute chest pain. In this paper, we review current data on the clinical utility of CCTA vs. stress testing in stable patients with suspected CAD.
Stress Testing for the Diagnosis of Coronary Artery Disease
Numerous studies and meta-analyses reported accuracy of stress testing for the diagnosis of CAD as defined by the gold standard of cardiac catheterization [4] [5] [6] [7] . Without imaging, the sensitivity of an exercise treadmill test for detecting CAD is only modest, i.e., approximately 70 %, while specificity is good (75-80 %) [6] . Adding myocardial imaging to standard exercise testing increases sensitivity for detecting CAD. Single-photon emission computed tomography (SPECT) is the most commonly used imaging adjunct to exercise testing in the USA. In meta-analyses, exercise SPECT yields sensitivity and specificity of 87 and 64 % vs. 82 and 75 % when combined with pharmacologic Bstress^ [4, 8] . Stress echocardiography is used less frequently than SPECT in the USA. In a meta-analysis, sensitivity and specificity for stress echocardiography was 85 and 77 % compared to 80 and 84 % with dobutamine [4, 8] . Overall, combined stress testing with imaging yields similar diagnostic performance for either SPECT or echocardiography, with sensitivity and specificity of approximately 80-90 and 70-80 %, respectively [9] . Remarkably, very few data are available from multicenter analyses using independent core laboratories. In general, multicenter data provide more realistic data on diagnostic test performance and typically reveal lower accuracies compared to the less rigorous analyses by specialized, single centers [10] . Furthermore, multicenter studies commonly require prospective enrollment and reduce inflation of sensitivity through referral or verification bias [11] [12] [13] . Recently, SPECT was compared to magnetic resonance imaging (MRI) in three multicenter studies revealing only modest accuracy for detecting CAD, with area under the curve (AUC) between 0.67 and 0.69 [14] [15] [16] . These results from studies with strong methodology suggest that the diagnostic accuracy of stress testing reported by less well-conducted single-center studies-and widely disseminated in analyses and practice guidelines-may be overestimated and may therefore not reflect clinical practice.
CCTA for the Diagnosis of Coronary Artery Disease
Diagnostic accuracy of CCTA in stable patients with suspected CAD has been tested in numerous single-center studies [17] [18] [19] . In meta-analyses, diagnostic accuracy of CCTA for identifying CAD compared to invasive coronary angiography yielded AUC between 0.97 and 0.99. Pooled sensitivity ranges between 98 and 99 %, specificity between 82 and 89 % [17, 18] . There are also several multicenter studies that reported AUCs of 0.93 and 0.96 for 64-slice detector technology among patients with different CAD risk characteristics [20] [21] [22] . The rigorously performed CORE-64 study [23] revealed an AUC of 0.93 for detecting ≥50 % stenosis on invasive coronary angiography, with sensitivity of 85 % and specificity of 90 %. A recent meta-analysis of 89 studies-including single and multicenter studies-reported a mean sensitivity of 0.97 (95 % CI 0.96-0.98) and mean specificity of 0.87 (0.85-0.90) for detecting angiographically significant (≥50 % stenosis) CAD [24] . The diagnostic accuracy data for CCTA have been largely consistent among studies when patient characteristics and methodology were considered [20] . In general, single-center results yield somewhat greater accuracy compared to multicenter studies due to the aforementioned reasons. In addition, sensitivity and specificity vary slightly from study to study because of reader specific thresholds, while predictive values may exhibit larger differences owing to their dependence on disease prevalence in the study population [20] . Even an accurate test will see decreasing negative predictive values if disease prevalence is high [20] . Furthermore, severe coronary calcification leads to decreased diagnostic accuracy for CCTA because of lower specificity. Yet, overall diagnostic performance remains excellent even when including patients with high calcium scores [20] .
Direct Comparison of Stress Testing to CCTA for the Diagnosis of CAD
Fewer data are available on the diagnostic performance of stress testing and CCTA in direct comparison. In a review of seven small clinical studies, CCTA yielded a sensitivity of 96 vs. 66 % by SPECT [9] . In a meta-analysis evaluating 11 studies with 1575 patients, which also included data from 16-slice CT technology, the investigators found a pooled sensitivity for CCTA vs. exercise electrocardiography and SPECT of 98 % (95 % CI 93 to 99 %) vs. 67 % (95 % CI 54 to 78 %) (p<0.001) and 99 % (95 % CI 96 to 100 %) vs. 73 % (95 % CI 59 to 83 %), respectively. The pooled specificity of CCTA was 82 % (95 % CI 63 to 93 %) vs. 46 % (95 % CI 30 to 64 %, p<0.001) for exercise electrocardiography and 71 % (95 % CI 60 to 80 %) vs. 48 % (95 % CI 31 to 64 %, p= 0.14) for SPECT [25•] . However, the retrospective study design and lack of core laboratory analysis in these studies render their results inconclusive. Recently, data were presented from the CORE320 multicenter study on a direct comparison of CCTA and SPECT revealing significantly greater accuracy for CCTA with an AUC of 0.91 vs. 0.69 [26••] . Similar to the single-center results from direct comparisons, sensitivity was markedly superior for CCTA (92 %) compared to SPECT (62 %) in this rigorously performed analysis. Furthermore, the diagnostic accuracy for SPECT was in line with data from the multicenter CE-MARC study, i.e., consistent with studies using meticulous methodology but deviant from results obtained in specialized SPECT centers without core laboratory analysis. In support of the findings from multicenter studies, the CATCH study reported a positive predictive value for CCTA to diagnose CAD of 71 % vs. only 36 % for standard of care using stress testing [27] . In the SCOT-HEART multicenter study [28••] , 9849 patients with stable chest pain were randomized to two groups, CCTA plus standard of care and standard of care alone, and were followed for a mean of 1.7 years. At 6 weeks, CCTA resulted in reclassification of CAD diagnosis in 558 (27 %) patients vs. 22 (1 %) in standard of care group (p<0.0001). Furthermore, the greater number of patients identified with CAD led to changes in preventative measures and to a 38 % reduction in fatal and nonfatal myocardial infarctions (p = 0.0527). Table 1 summarizes the diagnostic accuracy of CCTA vs. stress testing.
Prognostic Value of Stress Testing
There is abundant information on patient prognosis associated with stress test results. Most data derive from the nuclear medicine literature. In a meta-analysis with an average follow-up period of 22 and 20 months for pharmacological and exercise stress tests, respectively, the annualized rate of myocardial infarction and cardiac death was 0.65 % for patients who had a normal exercise SPECT but 1.78 % for a normal pharmacologic SPECT [38] . Conversely, adverse event rates were 4.30 % in patients with abnormal exercise SPECT and 9.98 % with abnormal pharmacologic SPECT results. In low-risk patients, a negative exercise test alonewithout imaging-is associated with excellent prognosis as seen in 1461 patients with a low-risk Duke Treadmill Score [39] . Exercise capacity adds to the imaging information with stress testing [40] . SPECT results were also evaluated for risk assessment in several large clinical studies. However, all these analyses were performed post hoc and thus are inflicted with the associated limitations. In a substudy of the COURAGE trial, there was significantly greater 5-year survival without myocardial infarction in patients with vs. without myocardial ischemia reduction following percutaneous coronary intervention (PCI); however, there were no statistically significant differences after risk adjustment [41] . In a second COURAGE imaging substudy, investigators reported similar 7-year event rates regardless of the extent of ischemia by SPECT or treatment assignment (medical therapy alone or PCI) [42] . In the BARI 2D SPECT substudy, the percent ischemic myocardium at 1 year after enrollment was not significantly associated with long-term adverse outcomes [43] . However, the prognostic value of SPECT was improved when percentage of myocardium with scar plus ischemic myocardium were considered together in this high-risk diabetic population. [43] . In the STICH imaging substudy, the presence of ischemia by SPECT or echocardiography did not predict outcome [44] . In the DIAD study of CAD screening using SPECT in 1123 asymptomatic patients with type II diabetes, abnormal stress testing results were predictive of adverse events but did not improve patient outcome [45] .
Prognostic Value of CCTA
A large body of literature has been recently published on the prognostic value of CCTA. While most data report intermediate follow-up times-similar to the nuclear medicine literature-a few long-term studies are also available. In a large meta-analysis, the association of cardiac events with CAD evaluation by 64- patients who underwent standard of care [47] . In a study assessing long-term follow-up after a normal CCTA, the annual rate of major adverse events was 0. 
CCTA vs. Stress Testing for the Prognosis of CAD
Few studies have directly compared CCTA vs. stress testing for CAD prognosis. In a study of 541 patients who underwent both CCTA and SPECT and were followed for a median of 672 days, CCTA analysis resulted in incremental prognostic value over SPECT for total mortality. The annualized mortality rate was 1.1 % in patients with normal SPECT results compared to 0.3 % in patients with normal CCTA [50] . In another study, outcome of patients after CCTA (n=693) was compared to that after SPECT (n=3067) using a matched cohort comparison study design, reporting similar annual mortality rates for CCTA (1.16 %) and SPECT (1.13 %) [51] . In the SPARC registry [52] , the 2-year event rate for nonfatal myocardial infarction and death was 0.7 % for CCTA, 1.6 % for SPECT, and 5.5 % for positron emission tomography (PET) in 1703 patients with suspected CAD. In a study by Shreibati et al. in 8820 patients undergoing CCTA and 132, 343 patients with stress testing, CCTA was associated with a 40 % reduction in acute myocardial infarction rates after 6-month follow-up [53] . Seven nonrandomized studies comprising 216,603 patients with a mean follow-up period of 20 months revealed an odds ratio for myocardial infarction of 0.53 (95 % CI, 0.39-0.72, p<0.001) for CCTA vs. exercise ECG/SPECT testing [54] . Table 2 summarizes the prognostic accuracy of CCTA vs. stress testing in different studies. 
Patient Management Based on Stress Test and CCTA Results
Available data suggests that CCTA may yield greater diagnostic and prognostic information in patients with suspected CAD compared to stress testing, but it remains unclear if such information translates into improved patient outcome. Intuitively, detection of nonobstructive CAD by CCTA is an important advantage over stress testing as it may trigger appropriate preventative measures and associated reduced rates of adverse advents [58] . However, because of the relatively low event rates in this population, surveillance of many patient years is required to demonstrate such effect. Indeed, several studies showed trends to lower myocardial infarction rates with CCTA guidance of management compared to the traditional approach with stress testing. In the SPARC study, the use of aspirin and lipid-lowering agents was higher following normal/nonobstructive CCTA findings when compared with SPECT [59] ; similar results were found in other studies for use of aspirin and lipid-lowering medication [60] [61] [62] . In the SCOT-HEART study, myocardial infarction rates were lower with the CCTA-guided management compared to the traditional approach using stress testing [ 
Cost Considerations
Several studies indicated greater downstream utilization of resources after CCTA use compared to traditional approaches. This may not be surprising since CCTA is more sensitive for detecting CAD than stress testing. A more sensitive test will diagnose a greater number of patients with disease who, in turn, will require more resources. On the other hand, CCTA also yields lower false positive rates than stress testing which may lower the rate of unnecessary referrals for cardiac catheterization. The relevant questions are if (1) the test utilization is appropriate and (2) if the test utilization is associated with better outcome. The latter typically requires longer follow-up which is rarely given in contemporary studies. In an interesting analysis, Neilson et al. investigated the impact of frontline exercise stress testing vs. CCTA on downstream test utilization in low-to intermediate-risk symptomatic patients [64] .
The authors found lower rates of downstream testing in the CCTA group compared with stress testing with fewer uses of cardiac catheterization. In a large retrospective cohort study for the diagnosis of CAD [60] , economic outcome of CCTA (1938 patients) was compared with stress testing (matched 7752 patients). The results suggested adjusted total health care and CAD expenditures to be 27 and 33 % lower, respectively, for patients who had CCTA compared with patients who had stress testing. In another retrospective observational study [65] , 1-year costs for CAD management and clinical outcomes in individuals without known CAD who had CCTA (1647 patients) were compared with matched patients (6588 patients) who had stress testing. CCTA testing was associated with lower health care costs by 25.9 % and lower probability of downstream testing and revascularization compared with stress testing. In another study, health care costs were lower in CCTA group (n=1647) compared to SPECT (n=6588), with similar rates of myocardial infarction and CAD-related hospitalization [65] .
Overall, an approach of initial CCTA testing in patients with suspected CAD appears to be cost-effective if it is chosen for the right patients, i.e., of intermediate pretest probability of CAD. Hulten et al. [66] estimated 15-23 % cost savings with the use CCTA vs. routine care for the overall population but found that CCTA cost exceeded that of routine care if the prevalence of obstructive CAD is greater than 28 %. Shreibati et al. [67] performed a retrospective, observational cohort study using claims data from a 20 % random sample of 2005-2008 Medicare fee-for-service beneficiaries aged >65 years with no claims for CAD in the preceding year, who received nonemergent, noninvasive testing for CAD (n=282,830), and compared CCTA with stress testing. CCTA was associated with higher likelihood of cardiac interventions and total health care spending. On the other hand, there was a trend toward lower adverse event rates with the CCTA strategy. Another recent study evaluated the 2-year costs in patients undergoing CCTA, PET, and SPECT reporting lower costs for SPECT imaging than CCTA or PET, primarily because of fewer subsequent invasive procedures [52] .
New Technologic Developments
There have been significant advancements in SPECT and CT technology in the last few years. Improvements for SPECT included better software and image reconstruction algorithms, e.g., iterative reconstruction, resolution recovery, and noise compensation algorithms, leading to lower radiation doses and better image quality [68] . Introduction of a new generation of gamma camera systems, which utilizes semiconductor detectors of cadmium zinc telluride (CZT) [69] , has led to faster acquisition time, lower radiation dose (about 1 mSv for a single injection) with preserved or higher image quality compared to conventional myocardial perfusion imaging by SPECT [70, 71] . Limited experience exists at this time in regards to the clinical experience with these improvements as these technologies are not widely available. Attenuation correction algorithms, on the other hand, are becoming increasingly prevalent at major medical centers. Several studies demonstrated improved specificity for the diagnosis of CAD in patients using attenuation correction, while sensitivity is similar to uncorrected SPECT [72, 73] .
For CCTA, the last few years saw large reductions in radiation dose, particularly, due to prospective scan triggering and iterative reconstruction algorithms, which may lead to submillisievert doses while maintaining acceptable image quality [74] . CT innovations that are at the brink of clinical use include CT myocardial stress perfusion imaging (CTP), CT-derived fractional flow reserve (FFR), and transluminal attenuation gradient (TAG) CT analysis. The combination of CCTA and CTP has improved accuracy of CCTA for the diagnosis of hemodynamically significant coronary stenosis [75] [76] [77] . CT myocardial stress perfusion imaging has recently been shown to be more accurate than SPECT for the diagnosis of CAD [78] . Combining CTA and CTP yielded an AUC of 0.87 for predicting CAD by conventional angiography which was associated with a corresponding myocardial perfusion defect by SPECT [79] . A different approach is the use of computational flow dynamics analysis of conventional CCTA data to predict pressure gradients (FFR) in the coronary arteries [80] . The application of CT-FFR has been evaluated in several studies demonstrating good diagnostic performance compared to invasively derived FFR [81] [82] [83] . However, the prolonged computational analysis duration and remote analysis required for CT-FFR currently presents an obstacle to clinical use. Another promising concept to derive hemodynamic information using CCTA uses TAGs to estimate blood flow restriction [84] . Preliminary data suggest improvement in diagnostic performance using TAG for detecting hemodynamically significant CAD over standard CCTA [85] . Overall, promising data exist for both stress testing and CCTA to further improved diagnostic performance and to potentially further lower radiation doses.
Discussion and Recommendations
Indirect and direct comparisons between CCTA and stress testing consistently revealed superior diagnostic performance by CCTA for the diagnosis of CAD as defined by standard definitions. The difference in diagnostic performance is particularly apparent for sensitivity while it is less pronounced for specificity. Both negative and positive predictive values are better for CCTA compared to stress testing. The results are not surprising as CCTA-like the reference standard by cardiac catheterization-is a test evaluating the coronary anatomy while stress testing assesses myocardial perfusion. Given the recent emphasis on hemodynamically significant as opposed to merely obstructive CAD, some argue for FFR as the more appropriate reference standard [86] . However, current practice guidelines in Europe and USA continue to define CAD according to anatomic criteria [87] [88] [89] . This is reasonable because there is a large body of evidence demonstrating high risk of adverse events in patients with obstructive CAD-regardless if the disease is associated with hemodynamic alterations or not [90, 91] . Increasing the threshold for the diagnosis of CAD to including hemodynamically significant CAD, e.g., using FFR, would leave many patients with obstructive CAD without a diagnosis of CAD and thus without current endorsement for important preventative measures. Recent data from several large clinical series demonstrate substantial adverse event rates in patients with nonobstructive CAD detected by conventional angiography or CCTA [58, 92•, 93••, 94] . These studies confirm the importance of detecting coronary atherosclerotic disease even when nonobstructive or Fig. 1 An algorithm is proposed for testing patients with suspected coronary artery disease. The algorithm considers current data and will require revisions pending new results. For example, it is conceivable that fewer patients will require cardiac catheterization in the future with improved noninvasive risk stratification hemodynamically insignificant. Therefore, we believe that the diagnosis of CAD should remain linked to lumen obstruction and not to its hemodynamic consequence. Confirmation of hemodynamic significance is important, however, when considering PCI in coronary artery lesions for symptom control as no benefit-and possible harm-occurs with coronary intervention in nonflow-limiting lesions [83] .
In regards to prognostic information and risk assessment, there is less clarity from head-to-head comparisons for CCTA and stress testing. However, it must be noted that the negative likelihood ratio for cardiac death and myocardial infarction associated with normal CCTA results is remarkably low and likely unmatched by stress testing when reviewing historical data. This again is expected given the inability of stress testing to detect nonobstructive disease which is associated with adverse outcome. Such advantage for risk assessment by CCTA has shown promising trends of improved patient outcome in the SCOT-HEART, PROMISE studies, and in the large CON-FIRM registry despite the lack of specific treatment prescriptions-a key limitation. We are still learning to optimally use the information provided by modern cardiac imaging, and we currently may over-test and under-treat patients. For example, most patients with evidence of CAD on CCTA have low-risk anatomy and require preventative measures along with medical therapy but are unlikely to benefit from cardiac catheterization/coronary artery revascularization. We may reduce risk to patients and lower cost by reserving invasive angiography for high-risk patients. Future studies need to more strongly consider specific management algorithms as opposed to randomizing patients to testing without further clinical guidance. Until such data are available, we are left with our best judgment of the available data to make decisions on patient management. As always, patient characteristics and preferences are critically important to individualize decisions. Furthermore, the decision to proceed with stress testing or CCTA in patients with suspected CAD should consider the performance of the available imaging laboratories. In general terms, we believe that a patient presenting with stable chest pain to a physician office will be best served with a CCTA if he is of intermediate pretest probability for CAD and if the CT laboratory has a track record of high-quality scan acquisitions using low radiation dose protocols along with excellent interpretation skills (Fig. 1) . Our recommendation is particularly based on the greater sensitivity of CCTA to detect CAD compared to stress testing and based on the opportunity to implement (or withhold) preventative measures depending on the presence and extent of atherosclerotic disease. On the other hand, it appears reasonable to proceed with an exercise stress test with or without echocardiography in low-risk patients as they are very unlikely to have CAD, and even the risk of low level of radiation by CCTA may not be outweighed by benefit in these patients. Examples of such patients may be women under the age of 40 presenting with atypical chest pain and no risk factors for CAD. In patients with high pretest probability, stress testing with imaging or direct referral to cardiac catheterization remain reasonable options at this time pending further data.
Compliance with Ethics Guidelines
Conflict of Interest AA Rahsepar and A Arbab-Zadeh both declare no conflicts of interest.
Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.
References
Papers of particular interest, published recently, have been highlighted as:
• Of importance •• Of major importance
